Business Context and Reporting Period
Company: Lifecore Biomedical, Inc. (LFCR)
Filing Type: Form 8-K (Current Report)
Report Date: June 1, 2023
Reporting Period: Third quarter of fiscal year 2023 ended February 26, 2023.
This filing serves as a notification that the Company issued a press release announcing its consolidated financial results for the specified period. The detailed financial data is contained in Exhibit 99.1 (Press Release), which is furnished but not deemed "filed" for purposes of Section 18 of the Exchange Act.
Key Financial Metrics
The provided text is a cover sheet and does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being available in the attached press release (Exhibit 99.1) but are not present in the source text provided for this summary.
Material Changes
The filing text does not provide specific details regarding material changes versus the prior comparable period. It only confirms the announcement of results for the third quarter of fiscal year 2023.
Guidance, Outlook, and Risks
The text does not include management commentary, forward-looking guidance, specific risk factors, or contingencies. It strictly references the existence of a press release containing the results.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated June 1, 2023) for actual revenue, net income, and EPS figures.
- Verify year-over-year and quarter-over-quarter growth rates in the attached press release.
- Check for any updated full-year fiscal 2023 guidance provided in the press release.
- Confirm the status of the Company's liquidity and debt obligations as detailed in the full financial report.